Skip to main content

Blood Loss, Surgical

3
Pipeline Programs
8
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

VarmX
VarmXNetherlands - Leiden
1 program
1
VMX-C001Phase 31 trial
Active Trials
NCT07288489Not Yet Recruiting800Est. Jan 2031
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
Haemate HSPhase 2
Becton Dickinson
Becton DickinsonFRANKLIN LAKES, NJ
1 program
1
AristaPhase 12 trials
Active Trials
NCT06822036Recruiting362Est. Jan 2027
NCT05522153Completed61Est. Jun 2023
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
Measurement of external blood lossN/A1 trial
Active Trials
NCT05316649Unknown45Est. Aug 2022
Artivion
ArtivionKENNESAW, GA
1 program
PerClot Polysaccharide Hemostatic SystemN/A1 trial
Active Trials
NCT02359994Completed324Est. Feb 2019
SPARK Biopharma
SPARK BiopharmaKorea - Seoul
1 program
Volta tAN SystemN/A1 trial
Active Trials
NCT06647017Not Yet Recruiting40Est. May 2025
Spark Biomedical
Spark BiomedicalTX - Dallas
1 program
Volta tAN SystemN/A
CSL Behring
CSL BehringIL - Bradley
1 program
Haemate HSPHASE_21 trial
Active Trials
NCT00618293Withdrawn0Est. Jul 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
VarmXVMX-C001
CSL BehringHaemate HS
Becton DickinsonArista
Becton DickinsonArista
SPARK BiopharmaVolta tAN System
Defence TherapeuticsMeasurement of external blood loss
ArtivionPerClot Polysaccharide Hemostatic System

Clinical Trials (7)

Total enrollment: 1,632 patients across 7 trials

NCT07288489VarmXVMX-C001

Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

Start: Mar 2026Est. completion: Jan 2031800 patients
Phase 3Not Yet Recruiting
NCT00618293CSL BehringHaemate HS

Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis

Start: Jan 2008Est. completion: Jul 20110
Phase 2Withdrawn
NCT05522153Becton DickinsonArista

Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study

Start: May 2021Est. completion: Jun 202361 patients
Phase 1Completed
NCT06822036Becton DickinsonArista

EFFICACY of INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION on the POSTOPERATIVE BLOOD LOSS in PATIENTS UNDERGOING RARP for the TREATMENT of PROSTATE CANCER

Start: Jan 2025Est. completion: Jan 2027362 patients
N/ARecruiting
NCT06647017SPARK BiopharmaVolta tAN System

Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures

Start: Nov 2024Est. completion: May 202540 patients
N/ANot Yet Recruiting
NCT05316649Defence TherapeuticsMeasurement of external blood loss

Blood Loss Quantification During Major Abdominal Surgery

Start: May 2021Est. completion: Aug 202245 patients
N/AUnknown
NCT02359994ArtivionPerClot Polysaccharide Hemostatic System

Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System

Start: Apr 2015Est. completion: Feb 2019324 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,632 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.